8-K: TELA Bio Reports 11% Revenue Growth in Q2 2024, Reaffirms Full-Year Guidance

TELA Bio announced an 11% year-over-year revenue increase for the second quarter of 2024, reaching $16.1 million, and reiterated its full-year revenue guidance of $74.5 million to $76.5 million.

Summary

• TELA Bio reported a revenue of $16.1 million for the second quarter of 2024, which is an 11% increase compared to the same period in 2023.
• The revenue growth was primarily driven by increased unit sales due to new customers, greater penetration within existing accounts, and expanding international sales.
• The company experienced a decrease in average selling prices due to a shift in product mix towards smaller-sized units, particularly with the introduction of robotically compatible OviTex IHR.
• Cybersecurity events, including a ransomware attack at a major GPO, negatively impacted revenue by reducing surgeries at affected facilities.
• Gross profit for the quarter was $11.1 million, representing 69% of revenue, compared to 70% in the same period last year, with the decrease attributed to higher charges for excess and obsolete inventory.
• Operating expenses increased to $22.6 million due to additional headcount and related costs.
• The company reported a net loss of $12.6 million for the quarter, compared to a net loss of $10.8 million in the same period of 2023.
• TELA Bio reiterated its full-year 2024 revenue guidance of $74.5 million to $76.5 million, representing a 27% to 31% year-over-year growth.
• The company expects revenue share payments from the sale of NIVIS Fibrillar Collagen Pack, ranging from $3 million to $7 million over the next eight quarters, starting in the third quarter of 2024.
• Cash and cash equivalents totaled $26.5 million as of June 30, 2024.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the revenue growth and reaffirmed guidance, but tempered by the net loss and impact of cybersecurity events. The company's focus on future growth and profitability is encouraging.

Positives

• TELA Bio achieved double-digit revenue growth of 11% in the second quarter of 2024.
• The launch of the robotically compatible OviTex IHR targets the high-volume inguinal hernia market.
• The company is set to receive revenue share payments from the NIVIS product, which will contribute to future revenue.
• TELA Bio has reiterated its full-year revenue guidance, indicating confidence in continued growth.
• The company is focused on improving sales productivity and efficiency under new sales leadership.
• TELA Bio believes its current cash position is sufficient to fund operations until profitability.

Negatives

• The company experienced a decrease in gross margin from 70% to 69% due to higher charges for excess and obsolete inventory.
• Operating expenses increased to $22.6 million, driven by additional headcount and related costs.
• TELA Bio reported a net loss of $12.6 million for the quarter, an increase from the $10.8 million loss in the same period last year.
• Cybersecurity events, including a ransomware attack, negatively impacted revenue by reducing surgeries at some facilities.

Risks

• Macroeconomic conditions, including the lingering effects of the COVID-19 pandemic, recessionary concerns, and inflationary pressures, could impact the company's ability to market its products.
• Cybersecurity events affecting hospital operations and procedural volumes pose a risk to revenue.
• The company's ability to achieve or sustain profitability is not guaranteed.
• There is a risk that the company may not gain market acceptance for its products or accurately forecast and meet customer demand.
• The company faces competition in the market.
• Data from earlier studies may not be replicated in later studies or indicative of future data.
• Development and manufacturing problems, capacity constraints, or delays in production could impact the company.
• The company's ability to maintain coverage and adequate reimbursement for procedures using its products is a risk.
• Product defects or failures could negatively impact the company.
• The total estimated consideration related to the NIVIS transaction is a risk.

Future Outlook

TELA Bio expects to deliver another year of high growth and has reiterated its 2024 revenue target of $74.5 million to $76.5 million. The company also anticipates revenue share payments from the NIVIS product and believes its cash position is sufficient to fund operations until profitability.

Management Comments

• TELA delivered double-digit growth in the second quarter notwithstanding some market disruptions from customer-targeted cyberattacks that we believe led to a shortfall in procedures at some of our largest or most rapidly growing contracted accounts, said Antony Koblish, President and CEO of TELA Bio.
• We believe many of these factors, including most notably a ransomware attack at one of our national GPOs, have been resolved and we are seeing signs of normalized growth returning in the third quarter.
• As a result, we expect to deliver another year of high growth and are reiterating our 2024 revenue target of $74.5 million to $76.5 million.
• Under new sales leadership, we are also intensely focused on improving the productivity and efficiency of our commercial organization and have initiated programs that will maximize sales and rep productivity and will provide operational leverage.
• We believe that with these efforts, as well as the contribution from the NIVIS revenue share, our cash and cash equivalents will be sufficient to fund us to profitability.

Industry Context

TELA Bio operates in the medical technology sector, specifically focusing on soft-tissue reconstruction solutions. The company's growth is influenced by trends in hernia repair, robotic surgery, and the demand for alternatives to permanent synthetic meshes. The market is shifting towards reinforced natural repair solutions, which TELA Bio is positioned to capitalize on.

Comparison to Industry Standards

• TELA Bio's 11% revenue growth in Q2 2024 is a positive sign, but it is important to compare this to other medical device companies in the soft tissue repair market.
• Companies like Integra LifeSciences and ACell, which also offer biologic and tissue-based products, have shown varying growth rates, and a detailed comparison would be needed to assess TELA Bio's performance relative to these competitors.
• The company's gross margin of 69% is within the range of other medical device companies, but the decrease from 70% in the previous year is a point of concern.
• The recurrence rates of TELA Bio's OviTex products, as shown in clinical studies, are generally favorable compared to traditional synthetic meshes and some biologic alternatives, such as Strattice and Surgimend, but direct head-to-head comparisons are limited by differences in patient populations and study designs.
• The company's focus on robotic compatibility with products like OviTex IHR aligns with the growing trend of minimally invasive and robotic procedures in surgery, which is a key differentiator.

Management Changes

Stakeholder Impact

• Shareholders may be encouraged by the revenue growth and reaffirmed guidance, but concerned about the net loss and cybersecurity issues.
• Employees may be impacted by the company's focus on improving sales productivity and efficiency.
• Customers may benefit from the launch of new products like the robotically compatible OviTex IHR.
• Suppliers may see increased demand for TELA Bio's products.
• Creditors may be reassured by the company's cash position and revenue growth.

Next Steps

• TELA Bio will continue to focus on improving sales productivity and efficiency.
• The company will work to maximize sales and rep productivity.
• TELA Bio will continue to expand its commercial organization.
• The company will monitor and address any further cybersecurity risks.
• TELA Bio will continue to develop and launch new products.

Key Dates

Keywords

TELA Bio, soft-tissue reconstruction, OviTex, hernia repair, medical technology, revenue growth, cybersecurity, robotics, NIVIS, reinforced tissue matrix